Answers are grounded in this paper and cite their sources.
Analysis reveals VDAC1 and VDAC2 as key prognostic biomarkers in hepatocellular carcinoma, suggesting their role in treatment strategies.
VDAC1 and VDAC2 are prognostic biomarkers and therapeutic targets in HCC, with genetic and immune interactions jointly influencing outcomes, supporting their potential for patient risk stratification and targeted or immune-based therapies.
No takes yet. Share an insight, caveat, or question.
Deng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: